Mabwell (Stock Code: 688062.SH) is an innovative biopharmaceutical company with a comprehensive presence in the pharmaceutical industry value chain. The company is dedicated to providing more effective and accessible therapies and innovative medicines to meet global medical needs. Since 2017, Mabwell has established an advanced R&D system that covers target discovery, early discovery, druggability, preclinical and clinical research, and manufacturing transformation.

Mabwell's robust R&D engine has resulted in 14 pipeline products at different stages of development, including 10 novel drug candidates and 4 biosimilars. These products target therapeutic areas such as oncology, autoimmune diseases, metabolic disorders, ophthalmologic diseases, and infectious diseases. Currently, two products have received approval and are in commercialization, one product is undergoing MA approval preparation, and two products are in pivotal trials.

The company is actively engaged in significant research projects, including one national major scientific and technological special project for "Significant New Drugs Development," two projects for National Key R&D Programmes, and various provincial and municipal science and technological innovation initiatives.

Mabwell places a strong emphasis on manufacturing quality and compliance. The Taizhou factory maintains in-house manufacturing capabilities compliant with international Good Manufacturing Practice (GMP) standards regulated by the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). Additionally, a large-scale manufacturing facility in Shanghai is currently under construction.

Mabwell's mission is "Explore Life, Benefit Health," and its vision is "Innovation, from ideas to reality." For more information, please visit their website at www.mabwell.com.